The present invention relates to a combination product and its use in therapy.

The present invention relates to a combination product and its use in therapy.

The invention relates to methods and compositions for use in the treatment and prevention of ocular diseases or conditions associated with neovascularization and/or inflammation.

Disclosed is a secure telephone call management system for authenticating users of a telephone system in an institutional facility. Authentication of the users is accomplished by using a personal identification number, preferably in conjunction with speaker independent voice recognition and speaker dependent voice identification. When a user first enters the system, the user speaks his or her name which is used as a sample voice print. During each subsequent use of the system, the user is required to speak his or her name. Voice identification software is used to verify that the provided speech matches the sample voice print. The secure system includes accounting software to limit access based on funds in a user's account or other related limitations. Management software implements widespread or local changes to the system and can modify or set any number of user account parameters.

Disclosed is a secure telephone call management system for authenticating users of a telephone system in an institutional facility. Authentication of the users is accomplished by using a personal identification number, preferably in conjunction with speaker independent voice recognition and speaker dependent voice identification. When a user first enters the system, the user speaks his or her name which is used as a sample voice print. During each subsequent use of the system, the user is required to speak his or her name. Voice identification software is used to verify that the provided speech matches the sample voice print. The secure system includes accounting software to limit access based on funds in a user's account or other related limitations. Management software implements widespread or local changes to the system and can modify or set any number of user account parameters.

The present application relates to a pharmaceutical combination, comprising: a) a prophylactically and/or therapeutically effective amount of ascorbic acid or a derivative thereof; and b) a prophylactically and/or therapeutically effective amount of a second therapeutic agent selected from the group consisting of: a Notch signaling pathway inhibitor, an HH signaling pathway inhibitor, a Porcupine inhibitor, an RXRα inhibitor, Niclosamide, a CK1a inhibitor, and a Frizzled receptor inhibitor.

The present application relates to a pharmaceutical combination, comprising: a) a prophylactically and/or therapeutically effective amount of ascorbic acid or a derivative thereof; and b) a prophylactically and/or therapeutically effective amount of a second therapeutic agent selected from the group consisting of: a Notch signaling pathway inhibitor, an HH signaling pathway inhibitor, a Porcupine inhibitor, an RXRα inhibitor, Niclosamide, a CK1a inhibitor, and a Frizzled receptor inhibitor.

Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound. In an embodiment, the aryladamantane compound is [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], or a pharmaceutically acceptable salt thereof.

Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound. In an embodiment, the aryladamantane compound is [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], or a pharmaceutically acceptable salt thereof.

Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound. In an embodiment, the aryladamantane compound is [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], or a pharmaceutically acceptable salt thereof.